Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 466 participants.
Also called NCT04263922
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 466 participants
- Sponsor
- Registry
-
NCT04263922
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT04263922. Randomized; double masking; primary purpose treatment. Start 2020-06-30 (actual); primary completion 2025-10-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3
- Condition
- Renal Insufficiency, Chronic
- Intervention (Drug)
- Huaiqihuang granules
- Intervention (Drug)
- Valsartan capsule
- Lead sponsor
- The First Affiliated Hospital of Dalian Medical University
- Collaborator
- Huazhong University of Science and Technology
- Collaborator
- LinkDoc Technology (Beijing) Co. Ltd.
Record details
- Record id
cardio:ct-nct04263922- Content hash
8a21e48c6e4641e0baed00c102469cd3b7093354178158a8f51eb28f30303b4a